Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 70Years
All Genders
NCT05329636

Auto Fecal Microbial Transplant Post Helicobacter Pylori Antibiotic Therapy

Led by Tel-Aviv Sourasky Medical Center · Updated on 2024-07-08

30

Participants Needed

1

Research Sites

405 weeks

Total Duration

On this page

Sponsors

T

Tel-Aviv Sourasky Medical Center

Lead Sponsor

W

Weizmann Institute of Science

Collaborating Sponsor

AI-Summary

What this Trial Is About

Current guidelines mandate Helicobacter pylori (H. Pylori) eradication with 2-3 antibiotics for 14 days ,This may result in multiple side effects and in eradication of important bacterial species to human health, exposing humans to multiple disease conditions. Preservation of fecal microbiome prior to antibiotic therapy and auto-transplantation of the microbes post H. pylori eradication, will enable avoiding eradication of beneficial microbial populations and perhaps protect from consequent disease conditions.

CONDITIONS

Official Title

Auto Fecal Microbial Transplant Post Helicobacter Pylori Antibiotic Therapy

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18-70 years old
  • Confirmed positive H. pylori infection by breath test or gastric biopsy
  • Intended to receive antibiotic therapy for H. pylori eradication
Not Eligible

You will not qualify if you...

  • Severe systemic diseases affecting the microbiome (e.g., heart disease, type 2 diabetes, chronic liver or kidney failure)
  • Antibiotic use within 2 months prior to enrollment
  • Planned antibiotic use within 2 months for reasons other than H. pylori
  • Unable to complete study procedures (swallow capsules or hold enema for 15 minutes)
  • Pregnancy
  • Unable to provide informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Dep. of Gastroenterology, Tel Aviv Sourasky Medical Center

Tel Aviv, Israel

Actively Recruiting

Loading map...

Research Team

N

Nitsan Maharshak, MD

CONTACT

R

Rony Izhar, PHD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here